Literature DB >> 25485916

30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: characteristics and preventability.

Andrew S Epstein1, Christopher Crosbie, Steven C Martin, Barbara Egan, Tabitha N Goring, Douglas J Koo, Chhavi B Kumar, Cori Salvit, Marinela Capanu, Joanna Chou, Leonard B Saltz.   

Abstract

PURPOSE: The Centers for Medicare and Medicaid Services recently initiated readmission reduction programs for certain noncancer index admissions. Intrinsic to this policy is the assumption that such readmissions are reasonably preventable and are due to inadequate management. For cancer patients, readmission frequency, characteristics, and their preventability have not been extensively evaluated.
METHODS: We first electronically searched medical records of patients on our gastrointestinal oncology inpatient service to identify patients who had been discharged and then readmitted within 30 days. However, electronic review resulted in insufficient granularity of clinical records. Therefore, 50 of them were randomly selected for exhaustive manual review to assess the reasons for index admission and readmission, the nature of the index admission discharge plan, and whether the readmission was reasonably preventable or not, based on prespecified criteria.
RESULTS: Between September 1, 2008, and March 1, 2013, 3995 gastrointestinal medical oncology patients had an index admission, of whom 876 (22%) had ≥ 1 readmission within 30 days. From the 50 manually reviewed records, the most common diagnosis categories for either the index admission or the readmission were infection, pain, and gastrointestinal issues. For 64% of these patients, the diagnoses of the index admission and the readmission were different. Disagreement between the care team and patient/family about the index admission discharge plan was documented in 10%. The readmission was determined to be preventable in 1 (2%) of the 50 manually reviewed cases.
CONCLUSIONS: Readmissions in this cancer population are common and reflect the refractory nature of these diseases and the high disease burdens. The vast majority of readmissions in this population, by our criteria, were not preventable. Our ongoing research in this vulnerable population includes efforts to better characterize and communicate care options, especially in the cases in which there was disagreement between the care team and patient/family.

Entities:  

Mesh:

Year:  2014        PMID: 25485916     DOI: 10.3810/hp.2014.12.1157

Source DB:  PubMed          Journal:  Hosp Pract (1995)        ISSN: 2154-8331


  5 in total

1.  Predictors of hospital readmission among older adults with cancer.

Authors:  Peggy Burhenn; Can-Lan Sun; Kevin S Scher; Joyce Hsu; Punita Pandya; Ching-Yi Chui; Anait Arsenyan; Dale Mitani; Rachel Morrison; Vani Katheria; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2020-03-25       Impact factor: 3.599

2.  Preventability of early vs. late readmissions in an academic medical center.

Authors:  Kelly L Graham; Ogechi Dike; Lauren Doctoroff; Marisa Jupiter; Anita Vanka; Roger B Davis; Edward R Marcantonio
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

3.  Intercycle Unplanned Hospital Admissions Due to Cisplatin-based Chemotherapy Regimen-induced Adverse Reactions: A Retrospective Analysis.

Authors:  Heber Rew Bright; Sujith J Chandy; Raju Titus Chacko; Selvamani Backianathan
Journal:  Curr Drug Saf       Date:  2019

4.  The 30-day hospital readmission and mortality after surgery in colorectal cancer patients.

Authors:  Mesnad S Alyabsi; Anwar H Alqarni; Latifah M Almutairi; Mohammed A Algarni; Kanan M Alshammari; Adel Almutairi; Nahar A Alselaim
Journal:  BMC Gastroenterol       Date:  2022-10-14       Impact factor: 2.847

5.  Towards a patient journey perspective on causes of unplanned readmissions using a classification framework: results of a systematic review with narrative synthesis.

Authors:  R G Singotani; F Karapinar; C Brouwers; C Wagner; M C de Bruijne
Journal:  BMC Med Res Methodol       Date:  2019-10-04       Impact factor: 4.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.